
|Videos|June 22, 2017
Nivolumab With or Without Ipilimumab in Gastroesophageal Junction Cancer
Author(s)Yelena Y. Janjigian, MD
Yelena Y. Janjigian, MD, attending physician, Memorial Sloan Kettering Cancer Center, discusses findings of CheckMate-032, a study of nivolumab (Opdivo) with or without ipilimumab (Yervoy) in patients with advanced/metastatic chemotherapy-refractory gastric, esophageal, or gastroesophageal junction cancer.




















